What is Salvia BioElectronics?
Founded in 2017 and headquartered at High Tech Campus Eindhoven in the Netherlands, Salvia BioElectronics is at the forefront of developing innovative neuromodulation therapies. The company's focus on chronic migraine and cluster headache positions it within a critical segment of the medical technology market. With clinical activities spanning the United States, Europe, and Australia, Salvia BioElectronics demonstrates a global reach and a commitment to advancing patient care through cutting-edge solutions.
How much funding has Salvia BioElectronics raised?
Salvia BioElectronics has raised a total of $60M across 1 funding round:
Series B
$60M
Series B (2025): $60M with participation from Invest-NL, Panakes Partners, Dolby Family Ventures, EIC IMPACT TRUST - EIC IMPACT FUND - Eastern Investment Centers, Shs Capital, Innovative Industrial Properties, Inkef, and Thuja Capital
Key Investors in Salvia BioElectronics
Invest-NL
Invest-NL is the national financing and development institution dedicated to fostering a sustainable and innovative Netherlands, accelerating and financing societal transitions in sectors such as Life Sciences & Health. They provide capital and expertise to invest in future solutions.
Panakes Partners
Panakès Partners is a Venture Capital investor that finances medical companies, early stage startups and SMEs, with extremely promising products and great ambition, in Europe and Israel, focusing on the medical device, diagnostics and healthcare IT fields.
Dolby Family Ventures
Dolby Family Ventures is an investment firm focused on supporting early-stage companies that address significant science and engineering challenges, particularly in the biotech and pharmaceutical sectors, with a focus on precision neuroscience.
What's next for Salvia BioElectronics?
The recent major strategic investment, alongside the overall enterprise-level funding, signals a pivotal growth phase for Salvia BioElectronics. This capital infusion is expected to accelerate the company's research and development efforts, expand its clinical trial reach, and potentially scale its commercialization strategies. The backing from prominent investors suggests strong confidence in Salvia's technology and its potential to disrupt the treatment landscape for debilitating neurological conditions.
See full Salvia BioElectronics company page
